Comparison of the DNA adducts formed by tamoxifen and 4-hydroxytamoxifen in vivo

• Published in: Carcinogenesis (New York) 1999-03, Vol.20 (3), p.471-477
• Main Authors: Beland, Frederick A., McDaniel, L. Patrice, Marques, M. Matilde
• Format: Article
• Language: English
• Subjects: Animals; Antineoplastic agents; Biological and medical sciences; Chemotherapy; Cytochrome P-450 Enzyme System - biosynthesis; Cytochrome P-450 Enzyme System - metabolism; DNA Adducts - chemistry; Enzyme Induction; Female; Isoenzymes - biosynthesis; Isoenzymes - metabolism; Liver - drug effects; Liver - enzymology; Medical sciences; Organ Size - drug effects; Pharmacology. Drug treatments; Rats; Rats, Sprague-Dawley; Tamoxifen - analogs & derivatives; Tamoxifen - pharmacology; Uterus - drug effects; Uterus - enzymology
• ISSN: 0143-3334; 1460-2180
• DOI: 10.1093/carcin/20.3.471

Tamoxifen is a liver carcinogen in rats and has been associated with an increased risk of endometrial cancer in women. Recent reports of DNA adducts in leukocyte and endometrial samples from women treated with tamoxifen suggest that it may be genotoxic to humans. One of the proposed pathways for the metabolic activation of tamoxifen involves oxidation to 4-hydroxytamoxifen, which may be further oxidized to an electrophilic quinone methide. In the present study, we compared the extent of DNA adduct formation in female Sprague–Dawley rats treated by gavage with seven daily doses of 54 μmol/kg tamoxifen or 4-hydroxytamoxifen and killed 24 h after the last dose. Liver weights and microsomal rates of ethoxyresorufin O-deethylation, 4-dimethylaminopyrine N-demethylation and p-nitrophenol oxidation were not altered by tamoxifen or 4-hydroxytamoxifen treatment. Uterine weights were decreased significantly and uterine peroxidase activity was decreased marginally in treated as compared with control rats. DNA adducts were assayed by 32P-post-labeling in combination with HPLC. Two major DNA adducts were detected in liver DNA from rats administered tamoxifen. These adducts had retention times comparable with those obtained from in vitro reactions of α-acetoxytamoxifen and 4-hydroxytamoxifen quinone methide with DNA. Hepatic DNA adduct levels in rats administered 4-hydroxytamoxifen did not differ from those observed in control rats. Likewise, adduct levels in uterus DNA from rats treated with tamoxifen or 4-hydroxytamoxifen were not different from those detected in control rats. These data suggest that a metabolic pathway involving 4-hydroxytamoxifen is not a major pathway in the activation of tamoxifen to a DNA-binding derivative in Sprague– Dawley rats.